Search | Clinical Trials Finder

Conditions: Type 1 Diabetes Mellitus
Interventions: Blood samples for safety, Patient reported outcome questionnaires, Analysis of T-cell subsets; Diagnostic Test · Behavioral
Lead sponsor: MacroGenics; Industry
Eligibility: 10 Years to 37 Years
Enrollment: 219 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Recurrent Breast Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Uterine Corpus Carcinoma, Triple-Negative Breast Carcinoma
Interventions: Gemcitabine, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Mirvetuximab Soravtansine, Pharmacological Study; Drug · Other · Biological
Lead sponsor: City of Hope Medical Center; Other
Eligibility: Not listed
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 2
States / cities: Duarte, California • Upland, California

Conditions: Pain
Interventions: Patient-controlled analgesia, morphine; Device · Drug
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 18 Years to 65 Years
Enrollment: 211 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Acquired Hemophilia A
Interventions: OBIZUR; Biological
Lead sponsor: Baxalta now part of Shire; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 6
States / cities: Gainesville, Florida • Detroit, Michigan • Durham, North Carolina + 2 more

Conditions: Healthy, Medical Record Systems, Computerized
Interventions: Hospitalists Results Manager; Behavioral
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Cervical Cancer
Interventions: Nelfinavir, Cisplatin, Pelvic External Beam Radiation Therapy, Brachytherapy, Pharmacokinetic Sampling, Cervical Biopsy, Pelvic Examination, Pap Smear, Audiogram, Proctoscopy, Cytoscopy, Renal Ultrasound, CT Scan, Whole Body PET/CT Scan; Drug · Radiation · Procedure
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older · Female only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Miami, Florida

Conditions: ADHD
Interventions: PRC-063 oral capsules, Placebo oral capsules; Drug
Lead sponsor: Purdue Pharma, Canada; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 8
States / cities: Bradenton, Florida • Lakeland, Florida • Maitland, Florida + 5 more

Conditions: Sickle Cell Disease
Interventions: Motixafortide, Natalizumab, Leukapheresis; Drug · Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Neuroblastoma, Osteosarcoma, Other Solid Tumor Cancers
Interventions: Humanized 3F8 Bispecific Antibody, Blood draw; Biological · Other
Lead sponsor: Y-mAbs Therapeutics; Industry
Eligibility: 1 Year to 17 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Covid19
Interventions: High volume evacuation (HVE), Extraoral vacuum aspirator (EVA), Hydrogen Peroxide, Placebo; Device · Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Constitutional Mismatch Repair Deficiency Syndrome, Lynch Syndrome, Malignant Glioma, Recurrent Brain Neoplasm, Recurrent Childhood Ependymoma, Recurrent Diffuse Intrinsic Pontine Glioma, Recurrent Medulloblastoma, Refractory Brain Neoplasm, Refractory Diffuse Intrinsic Pontine Glioma, Refractory Ependymoma, Refractory Medulloblastoma
Interventions: Biospecimen Collection, Conventional Magnetic Resonance Imaging, Diffusion Tensor Imaging, Diffusion Weighted Imaging, Dynamic Contrast-enhanced MR Perfusion, Dynamic Susceptibility Contrast-Perfusion-Weighted Imaging, Magnetic Resonance Spectroscopic Imaging, Pembrolizumab; Procedure · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 1 Year to 30 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 11
States / cities: Los Angeles, California • Palo Alto, California • Aurora, Colorado + 8 more

Conditions: Melanoma (Skin)
Interventions: buthionine sulfoximine, melphalan, microarray analysis, high performance liquid chromatography, laboratory biomarker analysis, pharmacological study, biopsy; Drug · Genetic · Other + 1 more
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 2
States / cities: Durham, North Carolina • Houston, Texas

Conditions: Locally Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Sotorasib, Trastuzumab Deruxtecan; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 9
States / cities: Sacramento, California • Tampa, Florida • Wesley Chapel, Florida + 4 more

Conditions: Breast Cancer
Interventions: Hypofractionated radiotherapy, Pembrolizumab infusion, Blood and tissue sampling; Radiation · Drug · Procedure
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Obesity, Morbid, Ventilator-Induced Lung Injury, Respiratory Failure
Interventions: Esophageal balloon, Intervention Spontaneous Breathing Trial (SBT) and Extubation, Control Spontaneous Breathing Trial and Extubation, Intervention Weaning after Tracheostomy, Control Weaning after Tracheostomy; Device · Procedure
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Greenville, North Carolina

Conditions: Staphylococcal Infections
Interventions: SA4Ag vaccine low dose, Blood draw, Colonization swab sample, SA4Ag vaccine mid dose, Blood sample, SA4Ag vaccine high dose, Placebo; Biological · Procedure
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 456 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 16
States / cities: Hollywood, Florida • South Miami, Florida • Overland Park, Kansas + 10 more

Conditions: Other Infectious Diseases
Interventions: Cefepime, Ceftolozane, Laboratory Biomarker Analysis, Meropenem, Piperacillin-Tazobactam, Tazobactam; Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cervical Cancer, Human Papillomavirus Infection
Interventions: Telephone Recall, Mailed HPV Self-Sampling Kit, Patient Navigation; Behavioral
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 30 Years to 65 Years · Female only
Enrollment: 111 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Metastatic Malignant Neoplasm in the Brain, Metastatic Solid Neoplasm, Recurrent Colorectal Carcinoma, Recurrent Pancreatic Carcinoma, Recurrent Solid Neoplasm, Stage IV Colorectal Cancer, Stage IV Pancreatic Cancer, Stage IVA Colorectal Cancer, Stage IVA Pancreatic Cancer, Stage IVB Colorectal Cancer, Stage IVB Pancreatic Cancer, Unresectable Solid Neoplasm
Interventions: Laboratory Biomarker Analysis, siRNA-transfected Peripheral Blood Mononuclear Cells (PBMC) APN401; Other · Biological
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Heart Disease, Lung Disease
Interventions: Thromboelastograph; Device
Lead sponsor: Stephen Esper; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Cirrhosis
Interventions: Vivify Kit; Device
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Adenocarcinoma of the Lung, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer, Stage II Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Interventions: 3-dimensional conformal radiation therapy, paclitaxel, bevacizumab, carboplatin, laboratory biomarker analysis; Radiation · Drug · Biological + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Acne Vulgaris
Interventions: Tazarotene (Fabior™), Tazarotene (Actavis), Vehicle foam; Drug
Lead sponsor: Actavis Inc.; Industry
Eligibility: 12 Years to 40 Years
Enrollment: 893 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 14
States / cities: Encino, California • Fremont, California • Brandon, Florida + 8 more

Conditions: Contrast Induced Nephropathy
Interventions: RenalGuard Therapy, Standard Therapy; Device · Drug
Lead sponsor: CardioRenal Systems, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 326 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2024
U.S. locations: 30
States / cities: Birmingham, Alabama • Torrance, California • Washington D.C., District of Columbia + 23 more

Search by objective public record fields.

Protege Extension Trial - Long Term Follow Up Trial for Subjects Who Completed the Protege Study (CP-MGA031-01)

Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer

Safety and Efficacy of Patient Controlled Analgesia in the Emergency Department

Prospective and Retrospective, Non-interventional Study to Evaluate the Safety and Effectiveness of Obizur in Real-life Practice

The Effects of a Results Management System on Physician Awareness of Post-Discharge Test Results

Safety Study of Nelfinavir + Cisplatin + Pelvic Radiation Therapy to Treat Cervical Cancer

PRC-063 Adult Laboratory Classroom Study in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

Motixafortide and Natalizumab to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD)

Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers

Evaluation of Aerosol in a Dental Clinic

Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma

A Phase I Trial of Normothermic Isolated Limb Infusion (ILI) With Melphalan Plus Buthionine Sulfoximine (BSO) in Patients With Locally Advanced Malignant Melanoma

Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation

BreastVAX: Radiation Boost to Enhance Immune Checkpoint Blockade Therapy

Providing Optimal PEEP During Mechanical Ventilation for Obese Patients Using Esophageal Balloon

Evaluation of a Single Vaccination With One of Three Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) in Healthy Adults Aged 18 to <65 Years

Comparative Study To Determine The Efficacy, Safety, And Tolerability Of Ceftolozane-Tazobactam

Prospective Evaluation of Self-Testing to Increase Screening (PRESTIS) Asian/Asian American Women Supplement

APN401 in Treating Patients With Recurrent or Metastatic Pancreatic Cancer, Colorectal Cancer, or Other Solid Tumors That Cannot Be Removed by Surgery

Evaluating the Use of Thromboelastography (TEG) in Patient's Requiring Extracorporeal Membrane Oxygenation (ECMO)

The Cirrhosis Outpatient Optimization, Readmission & Safety Study

Bevacizumab, Paclitaxel, Carboplatin, and Radiation Therapy to the Chest in Treating Patients With Locally Advanced Non-Small Cell Lung Cancer

A Study To Evaluate The Safety And Therapeutic Equivalence of Tazarotene Foam 0.1% in Subjects With Acne Vulgaris

Evaluation of RenalGuard® System to Reduce the Incidence of Contrast Induced Nephropathy in At-Risk Patients